Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6S0Y

Nanobody targeting influenza A matrix protein 2 ectodomain (M2e)

Summary for 6S0Y
Entry DOI10.2210/pdb6s0y/pdb
DescriptorM2e-VHH-23m, Matrix protein 2 (3 entities in total)
Functional Keywordsinfluenza a, fc gamma receptor iv, m2 matrix protein, nanobody, antiviral protein
Biological sourceLama glama
More
Total number of polymer chains4
Total formula weight31629.21
Authors
Van Molle, I.,De Vlieger, D.,Schepens, B.,Remaut, H.,Saelens, X. (deposition date: 2019-06-18, release date: 2020-01-22, Last modification date: 2024-10-09)
Primary citationDe Vlieger, D.,Hoffmann, K.,Van Molle, I.,Nerinckx, W.,Van Hoecke, L.,Ballegeer, M.,Creytens, S.,Remaut, H.,Hengel, H.,Schepens, B.,Saelens, X.
Selective Engagement of Fc gamma RIV by a M2e-Specific Single Domain Antibody Construct Protects Against Influenza A Virus Infection.
Front Immunol, 10:2920-2920, 2019
Cited by
PubMed Abstract: Lower respiratory tract infections, such as infections caused by influenza A viruses, are a constant threat for public health. Antivirals are indispensable to control disease caused by epidemic as well as pandemic influenza A. We developed a novel anti-influenza A virus approach based on an engineered single-domain antibody (VHH) construct that can selectively recruit innate immune cells to the sites of virus replication. This protective construct comprises two VHHs. One VHH binds with nanomolar affinity to the conserved influenza A matrix protein 2 (M2) ectodomain (M2e). Co-crystal structure analysis revealed that the complementarity determining regions 2 and 3 of this VHH embrace M2e. The second selected VHH specifically binds to the mouse Fcγ Receptor IV (FcγRIV) and was genetically fused to the M2e-specific VHH, which resulted in a bi-specific VHH-based construct that could be efficiently expressed in . In the presence of M2 expressing or influenza A virus-infected target cells, this single domain antibody construct selectively activated the mouse FcγRIV. Moreover, intranasal delivery of this bispecific FcγRIV-engaging VHH construct protected wild type but not γ mice against challenge with an H3N2 influenza virus. These results provide proof of concept that VHHs directed against a surface exposed viral antigen can be readily armed with effector functions that trigger protective antiviral activity beyond direct virus neutralization.
PubMed: 31921179
DOI: 10.3389/fimmu.2019.02920
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.81 Å)
Structure validation

226707

건을2024-10-30부터공개중

PDB statisticsPDBj update infoContact PDBjnumon